lemma health
Nemluvio (nemolizumab)
Available Online
Injection
Every 4-8 weeks
Copay Card Available
Available by Prescription
As Low as $0
Explore Other Treatments
How well does Nemluvio work?
Nemluvio is below average for atopic dermatitis "Biologics" treatments.
What is the evidence behind Nemluvio?
Nemolizumab significantly reduces itching (pruritus) in patients with moderate-to-severe atopic dermatitis. In clinical trials, patients saw 40-70% reduction in itch scores after 16 weeks of treatment, with improvements noticeable within the first few days.
What does the research say?
Study Summary

Nemolizumab, when used with topical treatments, reduced itching by 43% compared to 21% with placebo after 16 weeks. The medication also improved eczema severity and sleep quality in Japanese patients with moderate-to-severe atopic dermatitis.

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
Study Type
Clinical Trial
Studied Population
Total Patients: 215
Results
Nemolizumab reduced itching twice as much as placebo
Study Summary

Nemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.

Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
Study Type
Clinical Trial
Studied Population
Total Patients: 1,728
Results
Study Summary

Nemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.

Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus.
Study Type
Clinical Trial
Studied Population
Total Patients: 226
Severity: moderate to severe
Age: 18+
Results
What are other patients saying?
The medication improves skin symptoms and quality of life, including better sleep. Studies showed 45-78% improvement in eczema severity scores over 16-68 weeks of treatment.
What does the research say?
Study Summary

Nemolizumab, given as an injection every 4 weeks along with topical treatments, helped reduce itching by 66% and eczema severity by 78% over 68 weeks in patients with moderate-to-severe atopic dermatitis. The improvements lasted even after treatment ended, and the medication was generally safe to use.

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderateā€toā€severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, longā€term studies
Study Type
Clinical Trial
Studied Population
Total Patients: 303
Severity: moderate to severe
Age: ā‰„13 years
Results
Significant reduction in itching maintained over more than a year
Study Summary

Nemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.

Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
Study Type
Clinical Trial
Studied Population
Total Patients: 1,728
Results
What are other patients saying?
The most common side effects are mild and include nasopharyngitis (common cold), upper respiratory tract infections, and worsening of atopic dermatitis. Serious side effects are rare but can include severe allergic reactions.
What does the research say?
Study Summary

Nemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.

Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus.
Study Type
Clinical Trial
Studied Population
Total Patients: 226
Severity: moderate to severe
Age: 18+
Results
Study Summary

Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.

[Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].
Study Type
Review
Studied Population
Severity: moderate to severe
Age: 13+
Results
Continuous improvement and/or maintenance of itching reduction up to 68 weeks
What are other patients saying?
The medication is given as a subcutaneous injection every 4 weeks. It works by blocking interleukin-31, a protein that triggers itching in atopic dermatitis.
What does the research say?
Study Summary

Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.

[Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].
Study Type
Review
Studied Population
Severity: moderate to severe
Age: 13+
Results
Continuous improvement and/or maintenance of itching reduction up to 68 weeks
Study Summary

Nemolizumab is a new drug that targets IL-31, which is involved in causing eczema symptoms. The drug shows good results in reducing itch quickly and improving skin condition, with mostly mild side effects.

Nemolizumab for atopic dermatitis.
Study Type
Review
Studied Population
Severity: not available
Age: not available
Results
not available
What are other patients saying?
Taken every 4 weeks
What does the research say?
What are other patients saying?
Itch relief in as soon as 48 hours
What does the research say?
What are other patients saying?
Unique mechanism of action
What does the research say?
What are other patients saying?
Is Nemluvio Right For Me?
What is Nemluvio?
Nemolizumab (NEMLUVIO) is a prescription medicine that is given as an injection under the skin. It belongs to a class of drugs called monoclonal antibodies.
What are the requirements for taking Nemluvio?
Nemluvio might be right for you if:

  • You are an adult

  • You have prurigo nodularis (a chronic skin condition that causes intense itching and firm bumps on the skin)

How does Nemluvio work?
Nemolizumab works by blocking a protein called IL-31 receptor alpha. IL-31 is a substance in your body that causes itching, inflammation, and skin problems. By blocking the IL-31 receptor, nemolizumab helps reduce these symptoms.
Is it safe for children?
The safety and effectiveness of nemolizumab have not been established for children.
Is it safe for elderly patients?
About 27% of patients in clinical trials were 65 years or older. There weren't enough older adults in the studies to determine if they respond differently to the medicine compared to younger adults.
Is it safe during pregnancy?
There isn't enough information to know if nemolizumab is safe during pregnancy. The medicine can cross from mother to baby during pregnancy, especially in the third trimester. Animal studies showed some concerns about early deaths in newborns, but the significance for humans is unknown. Talk to your doctor about the risks and benefits if you are pregnant or planning to become pregnant.
Is it safe during breastfeeding?
It's not known if nemolizumab passes into breast milk or how it might affect a breastfed baby. The benefits of breastfeeding and the mother's need for the medicine should be weighed against any potential risks.